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Outcomes  
and Impact  
in 2018
10,590patients enrolled in clinical studies at the three HRB Clinical Research Facilities (CRFs)
197  
requests for data 
from the HRB’s 
NHIS received and 
responded to
272 people from 100 services trained to use the National Drug Treatment Reporting System (NDTRS) on LINK 
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It is an important time for health 
research in Ireland. Sláintecare creates 
cross-party consensus and a platform for 
transformation in the health services; 
Healthy Ireland aims to improve the 
health and well-being of the Irish 
population; and there is an increasing 
emphasis on the importance of evidence 
and evidence-based decision-making 
in healthcare and health policy.  In 
addition, new areas, such as big data, 
digitalisation and genomics, are 
beginning to emerge, so 2018 was an 
interesting and opportune year for both 
of us to have joined the Health Research 
Board, as Chairperson and Chief 
Executive respectively.
One of the first things that struck us on taking 
up our respective roles was the work ethic, 
teamwork and commitment of the people who 
work at the HRB. These qualities are central to 
the organisation’s ability to reach the ambitious 
targets outlined in HRB Strategy 2016–2020 
Research. Evidence. Action. We would like to 
commend the HRB team for their hard work 
and dedication throughout 2018. We would also 
like to thank the Board for their commitment 
and collective insights.
Three years into our plan, Strategy 2016–2020, 
Research. Evidence. Action, the HRB has 
demonstrated clear progress on its major 
goals and objectives, and during 2018 the 
organisation made strong advances in a 
number of important health research areas.
Health research leadership
The HRB’s growing leadership and influence are 
evident both nationally and throughout Europe. 
In Ireland, the HRB has been spearheading 
initiatives around open research, research 
integrity, and public and patient involvement 
in research. We provided key evidence to 
underpin decision-making in relation to a 
series of actions in Sláintecare and the Healthy 
Ireland strategy, and we co-hosted Ireland’s 
first National Drug Forum in partnership with 
the Department of Health’s Drug Policy Unit.
In Europe, we continued to hold leading 
positions on research policy groups in areas 
such as research integrity, biobanking, open 
research, and personalised medicine. All of 
these have significant implications for Irish 
researchers and it is essential that Ireland 
has a voice at the global table. We were also 
successful in securing Irish membership of 
the European Clinical Research Infrastructure 
Network (ECRIN), which will increase access for 
Irish patients to multi-national clinical trials. It 
will also make it easier for Irish researchers to 
extend their own trials internationally and help 
improve the quality of patient care. 
Health research delivery and impact
Key initiatives delivered by the HRB during 2018 
included: 
• Funding a selection of new awards worth 
more than €44.7 million (including co-
funding) which deliver on our strategic 
priorities. Some examples of these are:
Chairperson and Chief 
Executive Report 
Dr Darrin Morrissey 
Chief Executive
Prof Jane Grimson   
Chairperson
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 > Applying Research into Policy & Practice  
 Post-doctoral Fellowships
 > Applied Partnership Awards
 > Definitive Interventions and Feasibility  
 Awards
• Increasing participation in our new online 
data collection system, LINK, which is an 
ambitious programme designed to integrate 
our four national health information systems 
and receive data online from service 
providers in the areas of physical and 
intellectual disability, in-patient psychiatry, 
alcohol and drug treatment, and drug-
related deaths
• Delivering three evidence reviews, and 
completing six evidence briefs and two 
literature searches to support the decision-
making process at the Department of Health
• Launching HRB Open Research, Ireland’s first 
open access publishing platform
• Introducing a new Conference and Event 
Sponsorship scheme call to expand and 
streamline our support for health research 
conferences, seminars and events
• Redeveloping the HRB website.
Our activities have a direct impact on 
researchers, the research system, and the 
health services, which in turn delivers positive 
economic benefits for Ireland. Notably, in our 
research funding activity in 2018, we:
• Invested €44.7 million (including co-finding) 
to support 93 research projects across 13 
research-performing institutions
• Supported 228 research jobs
• Helped Irish researchers leverage more than 
€7 million from Horizon 2020 
• Involved 10,590 patients in 399 clinical 
studies underway at HRB Clinical Research 
Facilities (CRFs)
• Enabled 1,200 cancer patients to enrol in 
Cancer Trials Ireland clinical trials
• Developed health research career pathways 
which, as they take shape, promise to deliver 
a strong cohort of researchers who will 
continue to work in, and improve the Irish 
health system.
We supported an increasingly balanced 
research funding portfolio, with growth in the 
areas of population health and health services 
research. We have also made great strides to 
ensure gender balance across our international 
review panels and our investments, and we 
continue to have excellent gender balance 
among our grant recipients. Moreover, we 
are proud to say that gender balance on our 
Board was achieved in 2018, and this included 
the appointment of the HRB’s first female 
Chairperson by the Minister for Health.
Further examples and case studies which 
demonstrate what was achieved during the 
year are included throughout this report.
Health research partnership
€44.7m
to support 93  
awards across 13  
host institutions
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Working in partnership with other funders 
and research-performing bodies, we have 
supported many initiatives during the year, 
including: 
• HRB national co-funding initiatives with 
research charities, Science Foundation 
Ireland, and the Irish Research Council
• HRB international co-funding initiatives with 
Wellcome Trust, Fulbright, the US National 
Institutes of Health, and the Northern Ireland 
Health and Social Care R&D Division
• Awarding of €2 million to Evidence Synthesis 
Ireland to support capacity building across 
a broad range of evidence synthesis 
techniques on a cross-border basis, with 
Northern Ireland contributing €0.5 million of 
the funding
• Supporting the Department of Health by 
setting up a secretariat for the new Health 
Research Consent Declaration Committee 
and developing guidelines for the research 
community on the Health Research 
Regulations 2018
• Co-hosting the first National Drug Forum 
with the Department of Health Drug Policy 
Unit
• Providing data on the drug treatment 
situation in Ireland to the European 
Monitoring Centre on Drugs and Drug 
Addiction
• Working in partnership with the Health 
Service Executive (HSE) to enhance and 
develop quality and patient safety through 
targeted research projects
Future developments
Looking ahead, we will continue to focus on 
delivering high-quality research, information 
systems and evidence that positively impact 
people’s health, patient care and health service 
delivery in 2019, with a strong commitment 
to embedding research into the heart of the 
health system. 
A key action for the organisation in 2019 will be 
to commence the development of the HRB’s 
new strategic plan 2021–2025. We look forward 
to working in consultation with all of our health 
research stakeholders as we progress this. 
Prof Jane Grimson     
Chairperson
Dr Darrin Morrissey 
Chief Executive





Supporting research  
among medical  
charities 
€2.9m  
for 13 new 
projects
Research into executioner proteins, high-intensity 
interval training for cancer recovery, and gold 
nanoparticles to fight oesophageal cancer: these 
are just some of the projects announced by the 
Health Research Board (HRB) and the Medical 
Research Charities Group (MRCG) in 2018.
Ireland joins the  
European Clinical Research 
Infrastructure Network 
The HRB funded Irish membership 
of the European Clinical Research 
Infrastructure Network (ECRIN). This 
will increase access for Irish patients to 
multinational clinical trials. It will also 
make it easier for Irish researchers to 
extend their own trials internationally, 
and will help improve patient safety and 
quality of care.
The HRB published the latest  
drug treatment figures for Ireland
Drug treatment figures from the HRB showed that a 
total of 63,187 cases were treated for problem drug use 
(excluding alcohol) in Ireland between 2010 and 2016. 
Treated cases increased from 8,806 cases in 2010 to 
9,227 cases in 2016.
The number treated for cocaine use rose for the third 
year in a row. Opiates were still the main problem drug 
reported. Benzodiazepines increased both as the main 
problem drug and as an additional problem drug.
The HRB published 
intellectual, physical 
and sensory disability 
statistics
Figures highlight unmet needs 
and increased future demands 
on service provision for people 
with an intellectual, physical, 
and/or sensory disability.
in Horizon 2020 (H2020) 
funding in 2018 received by 
Irish health researchers.
Since H2020 began, Ireland 
has won €59.6 million in 
funding. This is 2.1% of 
the total available H2020 
research budget.
€7.1m
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First National 
Drugs Forum
Dr Brigitte Manteuffel, 
Georgia Health Policy 
Centre (GHPC), Minister 
Catherine Byrne, TD, Dr 
Darrin Morrissey, HRB and 
Dr Karen Minyard, GHPC.
The HRB and the 
Department of Health 
organised the first 
National Drugs Forum. The 
Forum aims to promote 
best practice for those 
working in addiction 
services; exchange 




Alcohol treatment in 
Ireland 2010 to 2016
7,643 in 2016
According to Dr Darrin Morrissey,  
Chief Executive, HRB:
‘Alcohol remains the main problem 
drug that people enter treatment 
for in Ireland. The trends outlined 
in this report provide good 
evidence to inform policy and plan 
services for alcohol treatment’.
The HRB published 
detailed psychiatric 
admissions and 
discharges data for 
2017
€2m 
Contributed by the HRB in all-island 
investment to build capacity in evidence-
informed decision-making.
Evidence Synthesis Ireland is funded by a €1.5 million 
investment from the HRB and €500,000 from the Research 
and Development Division of the Public Health Agency in 
Northern Ireland.
According to Dr Darrin Morrissey, Chief Executive at the HRB:
‘This investment … will support a key action in the 
Sláintecare report, which highlights that evidence should 
be at the core of routine decision-making across the 
health system’.
€752 million 
invested in health-related research 
between 2011 and 2015
The HRB published the first Irish report on national 
expenditure on health research in Ireland for the five 
years from 2011 to 2015.
According to Dr Maura Hiney, Head of Post-Award and 
Evaluation, HRB and lead author of the report:
'We now have a baseline for future  
trend analysis of Irish health  
research investment that  
allows us to track the  
effects on spending of  
changes in Government  
research and  
development  
strategy'.
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HRB-supported research highlights 
significant rise in uric acid levels in Irish 
patients
As a result of a study of more than 128,000 patients in the 
Irish health system, researchers found that uric acid levels 
increased by 21% over a nine-year period.
‘High levels of uric acid are directly linked to the 
development of several major diseases, including high 
blood pressure, diabetes, kidney disease, heart attacks and 
strokes’, says Professor Stack, Foundation Chair of Medicine 
at University of Limerick Graduate Entry Medical School and 
Consultant Nephrologist at University Hospital Limerick.
€5.8m
invested by HRB in 
new health researcher 
training programmes. The 
programmes will be in the 
areas of youth mental health, 
neonatal brain injury, elderly 
care, and multimorbidity in 
primary care settings.
The HRB compared 
the Irish drug 
situation with the 
rest of Europe
The HRB provided the Irish 
data for the European Drug 
Report 2018.
Working with other 
countries across Europe 
increases our understanding 
of drug markets and 
emerging trends. This is 
essential if we are going to 
reduce the harm caused 
by drug use and develop 
approaches to support 
recovery effectively.
Support for clinical trials
Statistics released by HRB Clinical 
Research Coordination Ireland (HRB 
CRCI) on International Clinical Trials 
Day 2018 show that there were 237 trial 
sites open in 2018. This was an increase 
from 134 trial sites open in 2014, when 
HRB CRCI was first established.
Health Research 
Regulations 2018 and 
the General Data 
Protection Regulation
The HRB created detailed 
guidance for researchers 
and set up a Secretariat 
to support the Health 
Research Consent 
Declaration Committee, 
which will be appointed by 
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The HRB published 
three evidence 
reviews for the 
Department of 
Health  
A new edition of Health 
Research in Action 
showcased some of the 
many ways that health 
research is making a 
positive difference to 







The HRB supported  
training of Ireland’s  
first FAIR data stewards
The HRB and eight partners 
(University College Dublin, Trinity 
College Dublin, the Royal College of 
Surgeons in Ireland, University College 
Cork, National University of Ireland, 
Galway, University of Limerick, 
Dublin City University, and Cancer 
Trials Ireland) sent 15 people to the 
Netherlands to become Ireland’s 
first FAIR (Findable, Accessible, 
Interoperable, Reusable) data 
stewards. Heart valve design  
wins HRB prize at the 
BT Young Scientist &  
Technology Exhibition 
Thomas Hayes, a sixth year student from 
Yeats College Galway, designed an artificial 
heart that met the International Organization 
for Standardization (ISO) standard for heart 
valve substitutes.
His prototype device uses a clever mix of 
stainless steel rings and bovine tissue that is 
potentially cheaper than current commercial 
options. The valve is also more flexible than 
current designs and could provide patients 
with a much better fit. 
In 2018, the HRB’s two disability databases, the 
National Intellectual Disability Database and 
the National Physical and Sensory Disability 
Database, were closed and work began on a new 
merged system: the National Ability Supports 
System (NASS).
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Professor Joel Selanikio 
delivered the keynote 
presentation at the HRB 
National Conference 2018: 
Big data in health – the 
opportunities and the 
challenges ahead.
Dr Sarah Craig, HRB, co-authored a research paper 
published in the Journal of Applied Research in 
Intellectual Disabilities, ‘Irish persons with intellectual 
disability moving from family care to residential 
accommodation in a period of austerity’. The analysis 
found that between 2009 and 2014, an estimated 200 
people per annum moved from family care to residential 
accommodation, but that the number of residential 
spaces available nationally fell by 9% in this period
The HRB funded four Fulbright-HRB Health 
Impact Awards to support Irish citizens to 
study, conduct research, or teach in the 
United States.
Dr Therese Lynn, HRB,  
co-authored a research paper, ‘Trends 
in injector deaths in Ireland, as recorded 
by the National Drug-Related Deaths 
Index, 1998–2014’, which was published 
in the Journal of Studies on Alcohol and 
Drugs. Between 1998 and 2014, a total of 
16,500 drug-related deaths in Ireland were 
documented by the National Drug-Related 
Deaths Index.
The HRB reduced its 
fossil fuel use and is 15% 
below its Sustainable 
Energy Authority of 
Ireland (SEAI) energy 
consumption target for 
2018. The reduction is the 
aggregation of many small 
changes that improve 
energy efficiency.
The HRB introduced a 
new conference and 
events funding scheme to 
streamline its approach 
to sponsorship and create 
capacity among the health 
research community to 
raise awareness, increase 








website to get people 
to the information 
they need faster.
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Key deliverables  
in line with  
HRB strategy  
2016 - 2020
1
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The HRB Strategy 2016–2020 charts a clear 
course for what the organisation will do over 
that time period.
This annual report highlights key achievements 
made during 2017 in line with the strategy 
objectives, and it showcases some examples of 
significant outcomes and successes.
Focus areas 
As the lead national agency for health research 
in Ireland, we have a responsibility to invest in 
the future as well as to meet the needs of today’s 
health system. Great ideas are the basis for 
many advances in healthcare. We have defined 
the following three distinct but complementary 
areas of focus that we consider to be the most 
appropriate to lead the HRB and its community 
over the period 2016–2020 and beyond:
• Address major health challenges.
• Support healthcare interventions.
• Address the research needs of the 
Irish health and social care system.
Enabling themes
Progress in the three focus areas will be 
enabled and maximised by policies and 
actions that affect all three:
• Supporting the exceptional researchers and 
leaders we need to undertake high-quality 
health research and generate evidence.
• Building a strong enabling environment for 
health research in Ireland and ensuring that 
we understand the outcomes and demonstrate 
the impacts of our investments.
• Ensuring that our policies and governance 























Address the research 
needs of the Irish health 











Figure 1.  
Core elements of HRB strategy 2016-2020
Our three focus areas and enablers are complementary and interdependent, 
and we will pursue them simultaneously throughout the period of the strategy.
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2018 Objectives: 
• Support high-quality, investigator-led, 
internationally competitive research.
• Develop and implement co-funding 
opportunities with international agencies and 
institutions.
Key items delivered in 2018 
• 23 awards, worth €12.3 million, were made in 
this focus area; of these, 22 awards involved 
international collaboration.
• Co-funded 13 awards worth €2.9 million 
under the ninth HRB-Medical Research 
Charities Group (MRCG) Joint Funding 
Scheme.
• Opened call for Investigator-Led Projects 
2019 in August 2018.
• Launched a new funding instrument 
focused on Parkinson’s disease research in 
partnership with the Medical Council, based 
on a bequest by Mr Patrick Quinn.
• Co-funded two large Investigator Awards and 
two Seed Awards with a combined value of 
€2.6 million under the Science Foundation 
Ireland (SFI)-HRB-Wellcome Research 
Partnership.
• Under the HRB strategy for engagement 
in European Union (EU) research, the HRB 
participated in five joint transnational calls in 
2018. These included four Joint Programming 
Initiatives (JPIs) – namely, two calls in the 
Joint Programme in Neurodegenerative 
Diseases (JPND) and two calls in the JPI on 
Antimicrobial Resistance (JPIAMR) – and one 
call in the ERA-Net on Personalised Medicine 
(ERA PerMed).
 •  Invested €1.2 million in six awards 
under joint transnational calls in 
health and social care aspects of 
neurodegeneration and in transnational 
research on antimicrobial resistance.
Focus area 1  
 
Address major  
health challenges
23
awards, worth  
€12.3m, were made  
in this focus area.
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Executioner proteins, high-
intensity interval training 
for cancer recovery, gold 
nanoparticles to fight 
oesophageal cancer, gut 
bacteria that may influence 
epilepsy, and light-activated 
polymers to kill infections 
are just some of the projects 
announced recently by the HRB 
and the MRCG.
The 13 research projects will 
address the research needs of 
specific patient populations 
and were awarded through 
the ninth HRB-MRCG Joint 
Funding Scheme. Eleven of 
the 14 projects have short 
video explanations about their 
projects.
Commenting on the awards, 
Dr Darrin Morrissey, Chief 
Executive, HRB said:
‘There are some very 
impressive ideas among these 
new research awards. The 
ingenuity of the research, 
as well as the impact that it 
will have on people’s lives 
demonstrates why it is so 
important to build a health 
research culture at the heart of 
our health services’.
Dr Avril Kennan, Chief 
Executive, MRCG noted:
‘This programme provides 
a particular opportunity for 
medical research charities 
to support research that is 
in response to what patients 
actually need. With matched 
funding from the HRB, charities 
can in effect double their 
research budgets’.
Dr Caitriona Creely, Programme 
Manager, HRB added:
‘The HRB-MRCG Joint Funding 
Scheme is an opportunity for 
the HRB to work with charities 
and support excellent research 
of relevance to patients, from 
understanding the cause 
of diseases, to looking for a 
cure, to focusing on care for 
people and families living with 
conditions day to day’.
The scheme runs approximately 
every two years. 
Case Study 1:  
Supporting research among medical charities – €2.9 million 
for 13 new projects
‘This programme provides a 
particular opportunity for medical 
research charities to support 
research that is in response to 
what patients actually need. With 
matched funding from the HRB, 
charities can in effect double their 
research budgets’.
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Professor Eileen Treacy is 
combining research, policy, 
and clinical practice to improve 
the lives of patients with rare 
diseases, and she would like 
more investment in Ireland in 
this important area, which often 
requires highly specialised care. 
Despite the name, rare diseases 
cumulatively are not rare. 
Thousands of known rare 
diseases affect at least 6% of 
the population in Europe, and in 
Ireland alone it is thought that as 
many as 300,000 people have 
such conditions.
‘While their diseases may be 
varied, what these patients 
have in common is often the 
chronic and highly debilitating 
nature of the conditions and 
the need for highly specialised 
multidisciplinary clinical care, 
psychosocial care and research 
which is often scarce and 
difficult to access, particularly 
in smaller countries such as 
Ireland’, explains Professor 
Treacy, who is Clinical Lead for 
the National Clinical Programme 
for Rare Diseases and 
Consultant Metabolic Physician 
at Temple Street Children’s 
University Hospital and the 
Mater Misericordiae University 
Hospital.
One of her current research 
interests is in the inherited 
condition called galactosemia, 
where newborns sustain organ 
damage from the milk sugar, 
galactose, in their diet.
‘Galactosemia affects 1 in 
16,000 births in Ireland each 
year’, Professor Treacy says. 
‘Studies from our group have 
shown that despite newborn 
screening and commencement 
of dietary galactose restriction, 
over 50% of patients in Ireland 
have developed significant 
complications from this 
condition’.
That sparked her to ask why, and 
she embarked on a programme 
of patient-oriented research 
supported initially by the HRB, 
the MRCG, and Temple Street 
Children’s University Hospital 
(TSCUH) Foundation.
The standard practice had 
been to remove virtually all 
galactose from the diet, which 
prevents liver failure in babies. 
Despite this treatment, many 
people with the condition go 
on to develop significant issues, 
such as intellectual difficulties, 
speech abnormalities, and 
infertility in females.
Professor Treacy led a 
team at TSCUH, along with 
Professors Pauline Rudd and 
Dr Peter Doran at University 
College Dublin, to explore 
the biochemistry of people 
with the condition. The team 
developed a patient registry for 
galactosemia and their HRB-
funded project analysed the 
biochemistry and genetics of 
the patients. 
They developed new tests to 
monitor how patients’ bodies 
respond to galactose, and 
now the National Centre for 
Inherited Metabolic Disorders is 
using the technology to monitor 
adults with the condition as they 
modify the galactose in their 
diet.
The HRB-funded research 
has contributed to revised 
international guidelines for 
galactosemia. It has also led to 
an international collaboration 
with the European Galactosemia 
Network (GalNet) (for which 
Professor Treacy is the Co-chair) 
and the development of an 
international registry, and she is 
now starting a new collaboration 
with Dr Peter Doran and other 
European investigators in 
this network to research new 
therapies for galactosemia.
Case Study 2: 
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2018 Objectives: 
• Support the design, conduct, and evaluation 
of intervention studies.
• Facilitate the coordination, enabling 
mechanisms, and national/international 
collaborations that improve the volume, 
quality, relevance, and impact of trials and 
intervention studies in Ireland.
Key items delivered in 2018
• Made 15 awards worth €11.9 million in this 
focus area.
• Invested €7.6 million in 11 Definitive 
Interventions and Feasibility Awards (DIFAs). 
These awards are designed to boost 
academic-led clinical trials and interventions 
and create a pipeline of research that can go 
on to become full-scale interventions in the 
future.
• Made 11 awards jointly with the Health and 
Social Care Division of the Public Health 
Agency in Northern Ireland under the 
European Commission’s INTERREG VA call for 
cross-border healthcare intervention trials.
• Made a further Opportunity-Led Funding 
Award in the area of stroke prevention with a 
value of €600,000 arising from the INTERREG 
VA programme, funded jointly with the Health 
and Social Care Division of the Public Health 
Agency in Northern Ireland.
• Provided €187,000 over two years to support 
the activities of the Irish Research Nurses 
Network, a key group in enabling clinical trials 
in Ireland.
• Completed interim reviews of the HRB’s four 
Clinical Trial Networks – perinatal health, 
primary care, critical care, and stroke – 
that received funding in 2014. These are 
substantial exercises in award oversight to 
help ensure that such a major investment 
(almost €9.8 million) remains on track and 
delivers value for money.
Focus area 2  
 
Support healthcare  
interventions
€11.9m
Made 15 awards, 
worth €11.9m, in this 
focus area.
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The HRB Collaboration in 
Ireland for Clinical Effectiveness 
Reviews (HRB-CICER) is a 
multidisciplinary research 
team supported by staff from 
the Health Information and 
Quality Authority (HIQA), the 
Royal College of Surgeons in 
Ireland (RCSI), and national 
and international clinical and 
methodological experts. 
It was established to deliver the 
systematic clinical effectiveness 
and economic literature reviews 
and the budget impact analysis 
needed for National Clinical 
Effectiveness Committee-
prioritised guidelines.
The team collaborates closely 
with Guideline Development 
Groups to ensure that the 
HRB-CICER’s work can be used 
to inform evidence-based 
recommendations. HRB-CICER 
was awarded €2.25 million 
in funding over the five-year 
period from 2017 to 2021.
In 2018, HRB-CICER provided 
two reviews that contributed to 
new National Clinical Guidelines 
for Adult type 1 diabetes mellitus 
(National Clinical Guideline No. 
17). This was published in June 
2018 by the National Clinical 
Effectiveness Committee.  These 
reviews were published as two 
annexes to the main report, 
‘Annex 1 - Economic evidence 
review’ and ‘Annex 2 - Budget 
impact analysis’.
Some of the key changes to 
service delivery arising from the 
report will include:
1. The national provision of 
a high-quality structured 
patient education 
programme to empower 
people with type 1 diabetes 
to effectively manage their 
diabetes and the external 
factors that can influence 
their blood glucose levels, 
such as exercise and stress
2. The standardisation of 
patient follow-up in diabetes 
clinics where patients are 
recalled at least every six 
months, and
3. Short courses for all staff 
who deliver care to people 
with type 1 diabetes in 
Ireland.
According to Dr Mairead 
O’Driscoll, Director of Research 
Strategy and Funding, HRB: 
‘This is a concrete example of 
the HRB delivering on one of 
its strategic aims, namely, to 
help policy-makers, service 
planners, and providers to make 
evidence-informed decisions’.
Case Study 3:  
Contributing to National Clinical Guidelines 
for type 1 diabetes
This is a concrete 
example of the HRB 
delivering on one of its 
strategic aims, namely, 
to help policy-makers, 
service planners, and 
providers to make 
evidence-informed 
decisions.
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In 2018, the HRB, with the 
support of the Department 
of Health, announced that it 
would fund Irish membership of 
the European Clinical Research 
Infrastructure Network 
(ECRIN), a European Research 
Infrastructure Consortium 
(ERIC). This will increase 
access for Irish patients to 
multinational clinical trials. It 
will also make it easier for Irish 
researchers to extend their own 
trials internationally, and will 
help improve patient safety and 
quality of care.
The HRB had engaged 
with ECRIN for many years 
and recommended Irish 
membership to the Department 
of Health. The Department of 
Health made the case to the 
Irish Government, which in turn 
gave the go-ahead for the HRB 
to advance Irish membership. 
The HRB began the formal 
application process in 2018 
and Ireland’s membership was 
ratified in late 2018.
Speaking at the time of the 
announcement, Dr Darrin 
Morrissey, Chief Executive, HRB 
said:
‘We welcome this Government 
decision which will advance 
Irish health research and 
patient care. It will introduce 
benefits for patients, such as 
access to trials and availability 
of new treatments. It will also 
give researchers in Ireland 
access to a portfolio of tools 
and services across Europe to 
improve the delivery of trials, 
and make it easier to extend 
their own trials internationally’.
Irish researchers will have full 
access to all the tools and 
services within ECRIN, such 
as trial preparation, protocol 
review, trial management, data 
centre certification, capacity-
building projects, and ECRIN-
supported trials.
Minister for Health, Simon 
Harris, TD, added:
‘Clinical trials are at the heart 
of improved prevention, 
diagnosis and treatment of 
diseases. While some trials 
can be conducted on a 
national level, many trials 
require access to large 
populations of patients and 
collaborations across centres 
and countries. Today’s decision 
represents an important 
development for current and 
future patients in Ireland and 
enhances Ireland’s reputation 
as a place to conduct 
industry trials. This will drive 
change and improve patient 
outcomes but also advance 
innovation, productivity and 
competitiveness’.
Case Study 4:  
The HRB to fund Irish membership of the European 
Clinical Research Infrastructure Network
‘This will drive change 
and improve patient 
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2018 Objectives: 
• Support research that addresses questions 
of national relevance for clinical and 
population health practice and for health 
services management, as well as the 
translation of research results into policy 
and/or practice.
• Provide high-quality, timely, and relevant 
data for policy, service planning, and 
research through the HRB’s National Health 
Information Systems (NHIS).
• Promote and support evidence synthesis 
and knowledge translation activities in order 
to help policy-makers, service planners, 
and providers make evidence-informed 
decisions.
Key items delivered in 2018
• Made 34 awards, worth €5.8m, in this focus 
area. It included: 
 > Investing €1.3 million in our Applied  
 Partnership Awards scheme. A total  
 of seven awards were made in 2018,  
 with co-funding of €240,000 provided  
 by healthcare organisations.
 > Awarding €2 million to Evidence   
 Synthesis Ireland in order to support  
 capacity building across a broad range  
 of evidence synthesis techniques,  
 including Cochrane systematic reviews.  
 This award is on a cross-border basis,  
 with the Health and Social Care   
 Research and Development Division of  
 the Public Health Agency in Northern  
 Ireland contributing €500,000   
 of the funding.
 > Conducting an in-depth review of our  
 Research Collaborative in Quality  
 and Patient Safety Awards scheme.  
 This scheme is run jointly with the  
 Health Service Executive (HSE) and the  
 Royal College of Physicians of Ireland  
 (RCPI).
 > Awarding €1.5 million to Wave 4 of the  
 Intellectual Disability Supplement (IDS)  
 of The Irish Longitudinal Study on  
 Ageing (TILDA).
 > Supporting 25 new awards worth almost  
 €1 million under the Knowledge   
 Exchange and Dissemination Scheme.
• Participated as a partner in a successful 
EU Horizon 2020 Science with and for 
Society (SWAFS) project to develop standard 
operating procedures for research integrity. 
HRB involvement will ensure that Ireland 
can influence the broader policy agenda in 
Europe in this area while at the same time 
ensuring coordination of Irish research 
integrity practices.
• Published three HRB NHIS annual reports.
• Published five national bulletins, generated 
Focus area 3  
 
Address the research 
needs of the Irish health 
and social care system
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five infographics, and produced 45 quarterly 
performance indicator reports to provide 
clear and concise information to assist 
policy-makers and service planners.
• Completed and submitted nine peer-
reviewed journal articles based on NHIS 
data. Seven were published in 2018, with the 
remaining two expected to be published 
during 2019.
• Trained 272 people from approximately 100 
services on the LINK system for the National 
Drug Treatment Reporting System.
• Collected data on behalf of the Road Safety 
Authority, the National Directorate Fire and 
Emergency Management, and the National 
Office for Suicide Prevention.
• The HRB and the Department of Health’s 
Drugs Policy and Social Inclusion Unit hosted 
the first annual National Drugs Forum in the 
Aviva Stadium in November 2018.
• Published three evidence reviews, and 
completed six evidence briefs and two 
literature searches.
• Published four issues of Drugnet Ireland.
• The HRB’s National Drugs Library 
(drugsandalcohol.ie) updated five fact sheets, 
made functional and visual improvements to 
its interactive treatment tables, and ensured 
that all drugs publications released in 2018 
were made available in the electronic public 
library. The website had 190,610 user sessions 
during 2018 and 5,710 profile visits to its 
Twitter feed.
• Provided data on the drug situation in Ireland 
to inform European monitoring and trends 
in line with contractual commitments to the 
European Monitoring Centre for Drugs and 
Drug Addiction (EMCDDA).
The HRB’s National 
Health Information 
Systems (NHIS) provide  
high-quality, timely  
and relevant data for 
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More than 200 people 
attended, including 
practitioners in drug 
treatment, prevention, and 
harm reduction services, 
and local drugs and alcohol 
taskforces, in addition to 
health policy-makers.
The theme for the Forum 
was ‘Working better together 
by building communities of 
practice’. The event aimed 
to strengthen the capacity 
of existing communities 
of practice and to provide 
examples for collaborative 
working across the statutory, 
community, and voluntary 
sectors.
Opening the Forum, Minister 
for Health Promotion and 
the National Drugs Strategy, 
Catherine Byrne, TD said:
‘Implementing the actions from 
the National Drugs Strategy 
requires collaboration, and 
communities of practice 
are a great example of this 
partnership approach. 
Delegates here today will 
have the opportunity to share 
experiences and work together 
to shape policy going forward’.
Keynote presentations were 
delivered by two international 
experts: Dr Karen Minyard 
from the Georgia Health 
Policy Center at Georgia State 
University, who spoke about 
the centre’s recent evidence 
review on dual diagnosis and 
described how communities 
of practices can be effective 
vehicles for transferring 
evidence into practical work; 
and Professor Harry Sumnall 
of Liverpool John Moores 
University, who examined 
the evidence base for 
interventions in the prevention 
and social reintegration 
field. Both are internationally 
renowned scholars with 
vast experience in policy 
development and knowledge 
transfer.
The keynotes were followed by 
four parallel workshops about:
• Supporting prevention work 
in the community
• Dual diagnosis: using 
partnership and peer 
support as resources in 
treatment
• The role of social 
reintegration in recovery, 
and
• Harm reduction services: 
engaging with people who 
use drugs.
Case Study 5:  
The HRB and the Department of Health’s Drugs 
Policy and Social Inclusion Unit hosted the first 
annual National Drugs Forum
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The HRB’s information 
systems provide primary data 
and statistics on psychiatric 
admissions, drug and alcohol 
treatment, and drug-related 
deaths, in addition to 
information about use and 
future demand for disability 
services.
‘These datasets are rich veins 
of information with so much 
potential to inform other areas 
of health and social care,’ says 
Dr Hamish Sinclair, Director 
of Health Information and 
Evidence at the HRB.
‘For instance, data from our 
National Intellectual Disability 
Database contributed to a 
research paper in the Journal 
of Applied Research in 
Intellectual Disabilities. The 
paper’s title, ‘Irish persons with 
intellectual disability moving 
from family care to residential 
accommodation in a period of 
austerity’ tells you everything 
you need to know about the 
wider social context and the 
policy conversations that our 
data can influence’.
‘Another example of a research 
paper published using HRB data 
in 2018 was ‘Trends in injector 
deaths in Ireland, as recorded 
by the National Drug-Related 
Deaths Index, 1998–2014’.
‘This study published in the 
Journal of Studies on Alcohol 
and Drugs was the first to 
describe the trends in deaths 
among drug users who injected 
at or around the time of their 
death in Ireland between 
1998 and 2014. The analysis 
provided empirical evidence 
that can be used by policy-
makers to support the ongoing 
improvement of drug treatment 
services, harm reduction 
initiatives, and overdose 
prevention strategies for people 
who inject drugs’. 
HRB data can also be used by 
other State agencies to help 
them deliver on their strategic 
aims.
Dr Sarah Craig, Head of National 
Health Information Systems at 
the HRB, adds:
‘In 2018 the HRB began 
collaborating with the Office of 
the State Pathologist and the 
State Laboratory to undertake 
secondary analysis of existing 
National Drug-Related Deaths 
Index data. The two specific 
areas of research examined 
were cocaine-related 
deaths and Pregabalin-related 
deaths.
‘By working with experts in 
the fields of pathology and 
toxicology we are enhancing 
the use of existing data and 
contributing to research in the 
area of drug-related deaths’.
‘Another new 2018 collaboration 
was with the Economic and 
Social Research Institute (ESRI). 
The HRB will provide disability 
and psychiatric in-patient 
admissions data for their 
projection model of healthcare 
utilisation – the Hippocrates 
model – which they developed 
last year.
‘From the data provided by the 
HRB, population projections, 
by age and sex to 2030, will 
be developed and will form 
the basis for the projection of 
health and social care demand 
and expenditure to 2030’.
Case Study 6:  
Secondary use of HRB data – adding extra 
value and fostering collaboration between 
the HRB and other government agencies
HRB data can also be 
used by other State 
agencies to help 
them deliver on their 
strategic aims.
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2018 Objectives: 
• Attract the best people to health research 
by supporting excellent PhD training 
programmes.
• Provide opportunities for career 
development for postdoctoral researchers 
and emerging investigators.
• Work with higher education institutions, 
Hospital Groups, and the HSE to identify, 
develop, and support leaders in health 
research.
• Work with national and international 
partners to facilitate training and exchange 
opportunities that address skills gaps.
Key items delivered in 2018
• Made 87 awards worth €11 million under 
Enabler A, in line with our Health Research 
Careers Framework and action plan 2016–
2020, published in 2016.
• Supported 67 Summer Student Scholarships 
with funding of €200,000.
• The HRB Irish Clinical Academic Training 
(ICAT) Programme (established with 
Wellcome) recruited the second cohort of 
new doctors to participate in a PhD training 
programme for clinicians. The scheme will 
train 40 clinicians between 2016 and 2021.
• Invested €5.8 million in four awards under 
the new Collaborative Doctoral Awards 
in Patient-focused Research scheme for 
thematic cohorts integrating health and 
social care professionals with academic 
health researchers.
• The HRB-funded Structured Population 
and Health-services Research Education 
(SPHeRE) programme took in the final of five 
cohorts of 10 PhD students in population 
health and health services research (six HRB-
funded and four self-funded). A further €2.5 
million investment for the next three cohorts 
of PhD students was approved.
• Awarded €2.5 million for 10 new Applying 
Research into Policy and Practice 
Postdoctoral Fellowships and one Cancer 
Prevention Fellowship.
• Provided an opportunity for four HRB 
researchers to take up placements of 
three to six months in order to develop 
collaborations with US colleagues through 
the Fulbright-HRB Health Impact Awards.
• Launched the next round of the Emerging 
Investigator Awards, with awards to be made 
in 2019.
• Completed interim reviews of four Research 
Leader Awards that received funding in 2015. 
These are substantial exercises in award 
oversight in order to help ensure that such a 
major investment (in excess of €5.7 million) 
remains on track and delivers value for 
money.
Enabler A  
 
Support exceptional 
researchers and  
leaders
€11m
Made 87 awards,  
worth €11m  
under Enabler A.
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The four new programmes 
will train 18 people over the 
next five years. They span the 
areas of youth mental health, 
neonatal brain injury, care for 
older people, and managing 
multimorbidity in primary care 
settings.
The training programmes 
will equip health researchers 
with an extensive skill set that 
will allow them to go on and 
integrate research with patient 
care in their specialist clinical 
areas.
I am confident that these new 
researcher training programmes 
are going to make a long-term 
impact on patient care’, said 
Dr Mairead O’Driscoll, HRB 
Director of Research Strategy 
and Funding’.
According to Dr Annalisa 
Montesanti, Programme 
Manager, HRB:
‘These four successful awards 
were selected on the basis that 
each one brings a coherent, 
structured approach to training 
health researchers to doctoral 
level in their respective fields.
‘They all had strong links to 
the delivery of care and they 
leveraged existing HRB-funded 
programmes and centres. 
They also involved cross-
disciplinary and inter- sectorial 
collaborations, and they placed 
important emphasis on public 
and patient involvement’.
The Collaborative Doctoral 
Awards in Patient-focused 
Research scheme was 
developed as part of the Health 
Research Careers portfolio. 
This portfolio aims to provide 
a coordinated approach to 
training and supporting health-
related researchers and health 
professionals at every career 
stage. The four schemes were:
1. Doctoral program in youth 
mental health leadership 
(The YouLead Program)
 Principal investigator: 
Professor Gary Donohoe, 
National University of Ireland 
(NUI) Galway
 Award amount: €1.5 million
2. Neonatal Brain Injury 
Consortium Ireland
 Principal investigator: 
Professor Eleanor Molloy, 
Trinity College Dublin (TCD)
 Award amount: €1.5 million
3. ‘Right Care’: a programme 
of research to enhance safe 
and appropriate care for 
older patients in Ireland
 Principal investigator: 
Professor Tom Fahey, RCSI
 Award amount: €1.4 million
4. Managing complex 
multimorbidity in primary 
care: a multidisciplinary 
doctoral training programme
 Principal investigator: 
Professor Susan Smith, RCSI
 Award amount: €1.4 million
Case Study 7:  
€5.8 million for four new health researcher training 
programmes
These four successful 
awards were selected 
on the basis that each 
one brings a coherent, 
structured approach 
to training health 
researchers to doctoral 
level in their respective 
fields.
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‘Bio energetic exhaustion’ 
is the term coined by HRB-
funded researchers at TCD 
and St. James’s Hospital in new 
research to explain why immune 
cells in smokers do not work as 
they should.
Dr Laura Gleeson, a HRB-funded 
Research Fellow at St. James’s 
Hospital, explains:
‘In healthy people, immune 
cells in the lungs called 
macrophages switch on a 
special energy pathway when 
they encounter invading 
bacteria like tuberculosis (TB). 
This switch seems to be a vital 
cog in allowing the body to use 
its own defences to fight and kill 
the bug.
‘In this research project we 
compared these macrophages 
in smokers’ lungs to healthy 
people and we found that 
smokers’ immune cells had 
almost no energy available 
to fight infection. It was as if 
the smokers had ‘exhausted 
macrophages’ and this led to the 
TB being able to establish itself 
in their lungs’.
Professor Joe Keane, a HRB 
Clinician Scientist and a senior 
author on the paper, continues:
‘This is a really exciting finding 
because if we can now find a 
way to boost smokers’ immune 
systems so they don’t have 
‘exhausted macrophages’, then 
their immune system can get on 
with the job of eradicating the 
infection itself.
‘This personalised medicine, 
or immunotherapy approach, 
circumvents the need to 
develop new drugs to kill the 
bacteria, which we know from 
experience, bacteria eventually 
develop resistance to’.
The paper, ‘Cigarette Smoking 
Impairs the Bioenergetic 
Immune Response to 
Mycobacterium tuberculosis 
Infection’, was published 
in the American Journal of 
Respiratory Cell and Molecular 
Biology on 1 November 2018.
Along with the HRB funding, the 
research was supported by the 
Royal City of Dublin Hospital 
Trust.
Case Study 8:  
Immune cells in smokers’ lungs ‘too exhausted’ to 
fight tuberculosis
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2018 Objectives: 
• Work with the Department of Health and key 
stakeholders to shape the national research 
agenda in relation to health and social care.
• Provide leadership to shape the review, 
conduct, and governance of research.
• Contribute to, and benefit from, international 
developments in policy, regulation, and 
legislation relevant to health research and 
healthcare in Ireland.
• Invest in research infrastructure to promote 
excellence, critical mass, and coordination in 
order to support HRB strategic focus areas 
and the wider health community.
• Support Irish health researchers to 
participate in Horizon 2020 (H2020) and 
other European research programmes. 
Key items delivered in 2018
• Provided €3.4 million in funding to continue 
the activities of HRB Clinical Research 
Coordination Ireland (HRB CRCI) for a 
further three years. This initiative provides 
coordination, support, and signposting for 
clinical trial activity in Ireland.
• Commenced two in-depth evaluations of the 
clinical research infrastructure in Ireland and 
HRB investment in health research leaders 
(specifically the Research Leader Awards and 
Emerging Clinician Scientist Awards) in order 
to inform future calls in these areas.
• Actively promoted public and patient 
involvement (PPI) in research. This included:
 > Working with the five PPI Ignite Awards  
 to coordinate their capacity building  
 for PPI in research in higher education  
 institutions.
 > Delivering a public review process  
 for two schemes in 2018: the Definitive  
 Interventions and Feasibility Awards,  
 and the Applying Research into Policy  
 and Practice Postdoctoral Fellowships.
 > Planning for the ambitious expansion  
 of public reviews in 2019, with full  
 coverage of 144 applications to the  
 Investigator-Led Projects.
 > Having the first PPI members on a  
 selection panel.
• Took a leadership role in Open Science in 
Ireland with a number of initiatives. This 
included: 
 > Chairing a revision of the national  
 research integrity policy (Ensuring  
 Integrity in Irish Research) on behalf of  
 the National Forum on Research  
 Integrity.
 > Launching Ireland’s first open research  
 publishing platform, HRB Open   
 Research, in January 2018.
 > Conducting two training events to raise  
 awareness of FAIR (Findable, Accessible,  
 Interoperable, Reusable) research data.
 > Jointly chairing the National Open  
 Research Forum (NORF) with the Higher  
 Education Authority (HEA).
 > Participating in the drafting group for  
 a National Framework on the Transition  
 to an Open Research Environment, with  
 a wide national consultation process.
• Continued to improve HRB grant processes. 
This included:
 > Achieving excellent gender balance on: 
  - HRB selection panels, with 53%  
 female and 47% male representation,  
 and 
Enabler B  
 
Build a strong  
enabling environment
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  - Applicants’ success rates, with 29%  
 of female applicants and 28% of male  
 applicants successful. 
 > Being an active member of a global  
 forum for funders under the banner  
 of ‘Ensuring Value in Research’. The  
 Forum allows members to develop  
 best practice in a variety of areas, from  
 the selection of call topics to the  
 reporting of outputs and outcomes.
• Published a report entitled Health 
Research in Ireland: A study of activity from 
2011 to 2015 using the Health Research 
Classification System. This analysed health 
funding data from seven Irish agencies and 
two Government Departments in terms of 
research activity type and disease areas 
supported.
• Worked on an initiative to align research data 
management policy across Europe as part 
of the Science Europe Working Group on 
Research Data.
• Confirmed Irish membership of the EU Public 
Health Programme through the Department 
of Health, affording Irish researchers the 
opportunity to undertake policy- and 
practice-relevant health research.
• Chaired the International Consortium 
for Personalised Medicine (ICPerMed), a 
consortium of EU funding bodies established 
by the European Commission under the 
H2020 programme.
• Contributed to the health perspective in 
Ireland’s Preliminary Views on the 9th EU 
Framework Programme for Research and 
Innovation.
• Supported Irish researchers to compete for 
EU funding:
 > Irish researchers leveraged €7.1 million  
 in funding from H2020 programmes.
 > Seventeen Irish projects successfully  
 competed for funding in the H2020  
 Health Challenge, with Irish researchers  
 as partners. Highlights include: 
  - The HRB being a successful   
 partner in two projects, one an ERA- 
 Net project to support  the Joint  
 Programme in Neurodegenerative  
 Diseases Research (JPND) strategic  
 plan, and the other in a European Joint  
 Programme Co-fund on Rare Diseases.
  - Irish researchers being partners in  
 3 of the 10 projects funded in the area  
 of palliative care, amounting to €1.4  
 million in funding for Ireland.
  - Geraldine Leader of NUI Galway  
 drawing down more than €1.6 million  
 for a project on an integrated multi- 
 omic systems biology approach   
 to identify biomarkers for personalised  
 treatment and primary prevention of  
 autism spectrum disorder.
  - The HSE being successful as a   
 partner with the Irish    
 Centre for Emergency Management in  
 a project on assessing and   
 reducing cyber risks in hospitals   
 and care centres in order to protect  
 privacy, data, and infrastructures.
  - Five Irish companies receiving almost  
 €1.6 million in funding.
144
Piloting a public review 
process in 144 funding 
applications to the  
Investigator-Led  
Projects scheme.
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The HRB published the first 
Irish report on national 
expenditure on health research 
in Ireland for the five years 
from 2011 to 2015.
According to Dr Maura Hiney, 
Head of Post-Award and 
Evaluation, HRB and lead 
author of the report: 
‘We now have a baseline 
for future trend analysis 
of Irish health research 
investment that allows 
us to track the effects 
on spending of changes 
in Government R&D 
strategy’.
Seven national funding 
agencies (Enterprise Ireland 
(EI), the Environmental 
Protection Agency (EPA), 
the HRB, the Irish Research 
Council (IRC), the Marine 
Institute (MI), Science 
Foundation Ireland (SFI), and 
Teagasc) and two Government 
Departments (the Department 
of Agriculture, Food and 
the Marine (DAFM) and the 
Department of Children and 
Youth Affairs (DCYA)) provided 
data for this analysis.
Dr Darrin Morrissey, Chief 
Executive at the HRB, says:
‘Ireland makes significant 
public investments in health 
research, which deliver 
substantial societal and 
economic benefits. Health 
research attracts funding from 
many different sources and 
it is interesting to see how 
much co-funding non-public 
partners are contributing to 
the national public funding pot 
and who these partners are’.
Key findings
In total, there were 1,513 
health research awards, with 
a value of slightly more than 
€752 million, made between 
2011 and 2015. These awards 
supported research with many 
different objectives:
•  Expanding our knowledge 
and understanding of 
health and disease
•  Improving healthcare and 
services, strengthening the 
enterprise base
•  Building the capacity for 
and expertise in high-
quality health research, and
•  Generating the evidence 
to inform policy and 
regulation.
Cancer and neoplasms 
research received the greatest 
share of health-specific 
funding (€93.1 million; 21%), 
and funding was provided 
by all participating agencies 
except the MI. This is in line 
with results from similar 
analyses in the United Kingdom 
and Norway, where cancer 
and neoplasms research also 
accounted for the largest 
proportion of total funding.
Other health-specific health 
categories in which significant 
funding was awarded included 
infection (11%), neurological 
(11%), oral and gastrointestinal 
(9%), cardiovascular and stroke 
(10%), mental health (7%), 
and reproductive health and 
childbirth (6%).
Almost one-quarter of all 
funding €209 million supported 
the development of the 
infrastructure, networks, and 
platforms that enable health-
related research.
Co-funding accounted for 
€100 million of the total pot.
Case Study 9:  
Ireland invested €752 million in health-related 
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Case Study 10:  
HRB supporting success in EU 
Horizon 2020 health 2014 - 2018
€60m




The number of Irish 
researchers we helped 
to apply for EU funding 
(including over 100 
coordinators).
Supporting 74 
projects in areas 
from cancer to 
big data.
Irish researchers 
secured 2.1%  














IRISH RESEARCHERS ARE LEADING 
8 PROJECTS THAT SPAN
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2018 Objectives: 
• Ensure a high-performing working 
environment built on innovation, adaptability, 
and teamwork.
• Enable transparent and accountable 
decision-making based on the best possible 
information.
• Ensure that HRB systems and processes are 
robust, flexible, and scalable.
• Enhance recognition of the values of health 
research and the HRB’s role nationally and 
internationally.
Key items delivered in 2018
• Hosted the HRB National Conference 2018: 
Big data in health, which looked at the 
challenges and opportunities ahead for 
Ireland in this area.
• Introduced a new conference and events 
funding scheme in order to streamline 
the HRB’s approach to sponsorship and 
create capacity among the health research 
community to raise awareness, increase 
engagement, and transfer knowledge.
• Deployed a cloud-based software platform, 
OneTrust, which provides a centralised 
dashboard to manage all aspects of the 
revised General Data Protection Regulation 
(GDPR), such as cookie compliance, data 
breach reporting, and subject access request 
procedures.
• Conducted eight Data Protection Impact 
Assessments on HRB systems which process 
personal data.
• Reduced the organisation’s fossil fuel 
use; the HRB is 15% below its Sustainable 
Energy Authority of Ireland (SEAI) energy 
consumption target for 2018. The reduction 
is the aggregation of many small changes that 
improve energy efficiency.
• Launched a new mobile-optimised and 
standards-compliant HRB website to get 
people to the information they need faster.
• Reviewed and enhanced the HRB’s business 
planning and reporting mechanisms in 
order to meet the operational needs of the 
HRB staff and Board and the Department 
of Health, and also in order to improve 
decision-making and ensure best use of 
resources.
• Worked to establish a framework for 
greater employee resilience, employee 
engagement, and enhanced performance 
through initiatives such as the HRB’s Personal 
and Organisational Development (POD) 
programme and a greater emphasis on 
organisational training initiatives.
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More than 200 people 
attended the HRB National 
Conference 2018: Big data in 
health on 27 November 2018 in 
Dublin Castle.
A strong lineup of international 
and national speakers from 
diverse backgrounds brought 
the topic to life. Their 
contributions informed an 
insightful discussion, chaired 
by Miriam O’Callaghan, which 
looked at balancing big data, 
big business, and privacy.
As Andre Dekker, Professor 
of Clinical Data Science at 
Maastricht University, noted, 
‘The barriers to big data are 
not technical, they are ethical, 
political or administrative’.
Dr Joel Selanikio, CEO of 
Magpi and Assistant Professor 
of Pediatrics at Georgetown 
University Hospital, delivered 
the keynote presentation, 
‘Opening our minds to the 
potential of big data’. Two of 
the many insights from that 
presentation were that:
‘The cheap expertise of AI 
(artificial intelligence) is coming 
to health and healthcare. This 
will change clinical practice, 
and shift more of health – and 
health research – away from 
traditional healthcare’.
‘If you want to see what will 
happen in healthcare in 
the future, look at what is 
happening in retail today. 
People actually have more data 
on their own personal devices 
and it is by harnessing this that 
you will be able to predict what 
their health needs are in the 
same way Amazon can predict 
what will interest you when you 
have a profile with them’.
The overriding theme from the 
speakers was that there are 
many opportunities to safely 
harness health data in order to 
improve health and advance 
healthcare.
Keynote speakers included:
• Professor Jean-Christophe 
Desplat, Director, Irish 
Centre for High-End 
Computing (ICHEC) and NUI 
Galway
• Dr Howard Johnson, Clinical 
Lead of Health Intelligence, 
HSE
• Professor Andre Dekker, 
Professor of Clinical 
Data Science, Maastricht 
University, and
• Muiris O’Connor, Assistant 
Secretary, Department of 
Health 
All of the presentations were 
recorded and are available 





Case Study 11:  
HRB National Conference 2018 – Big data in health
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The revised General Data 
Protection Regulations (GDPR) 
which came into force during 
2018 built upon previous data 
protection directives with 
new and stronger rights for 
individuals. 
The HRB carried out a number 
of actions during 2018 in order to 
bolster compliance with the new 
regulation.
These steps included:
• Appointing a Data Protection 
Officer.
• Partnering with OneTrust, a 
data privacy management 
software vendor, which 
assisted us with our data 
mapping, cookie compliance, 
breach reporting, and 
subject access request 
procedures.
• Conducting eight Data 
Protection Impact 
Assessments on HRB systems 
which process personal data.
• Simulating two cyberattacks 
on our public-facing LINK 
and GEMS systems in order 
to test and verify their 
security standards.
• Drafting two new GDPR 
policies for data breaches 
and data subject access 
requests.
• Amending three existing 
policies for data privacy, data 
retention, and web cookies.
• Updating all of our data 
processing agreements with 
our data processors in order 
to ensure that they too were 
compliant with the additional 
obligations of the new GDPR.
• Conducting staff training 
specifically on handling 
personal data as per 
obligations set out in Article 
39(a) of the GDPR.
• Adopting a ‘data protection 
by design and data 
protection by default ethos’ 
into the organisation.
So, whether you are a grant 
applicant or grant holder, current 
or former employee, someone 
accessing our information 
systems, peer reviewer, 
contractor, member of the 
public using our National Drugs 
Library service, or a member of 
the public corresponding with us 
by phone, e-mail or otherwise, 
your data is safe with us.
Case Study 12:  
Your data is safe with us
Appendices
2
Health Research Board Annual Report 201834
Research. Evidence. Action. 35
Appendix A
List of HRB publications in 2018
HRB REPORTS
EVIDENCE REVIEWS
Daly A and Craig S (2018) Activities of Irish Psychiatric Units and Hospitals 2017. Main Findings. 
HRB Statistics Series 38 Dublin: Health Research Board.
Doyle A and Carew AM (2018) Annual Report of the National Physical and Sensory Disability 
Database Committee 2017. Main Findings. HRB Statistics Series 36. Dublin: Health Research 
Board.
Health Research Board (2018) Alcohol Treatment in Ireland 2010 – 2016. Dublin: Health Research 
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